Back
Piedmont Lithium 10K Form
Sell
38
PLL
Piedmont Lithium
Last Price:
12.26
Seasonality Move:
8.95%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-09 | 10Q | PLL/Piedmont Lithium Quarterly |
| 2024-02-29 | 10K | PLL/Piedmont Lithium Annual |
| 2023-11-09 | 10Q | PLL/Piedmont Lithium Quarterly |
| 2023-08-08 | 10Q | PLL/Piedmont Lithium Quarterly |
| 2023-05-05 | 10Q | PLL/Piedmont Lithium Quarterly |
| 2023-04-25 | 10K | PLL/Piedmont Lithium Annual |
Receive PLL News And Ratings
See the #1 stock for the next 7 days that we like better than PLL
PLL Financial Statistics
Sales & Book Value
| Annual Sales: | $39.82M |
|---|---|
| Cash Flow: | $-9.65M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $14.73 |
| Price / Book: | 0.9 |
Profitability
| EPS (TTM): | -4.09000 |
|---|---|
| Net Income (TTM): | $-79.02M |
| Gross Margin: | $5.68M |
| Return on Equity: | -25.05% |
| Return on Assets: | -22.16% |
Piedmont Lithium Earnings Forecast
Key Piedmont Lithium Financial Ratios
- The Gross Profit Margin over the past 35 years for PLL is 14.26%.
- The Selling, General & Administrative Expenses for PLL have been equal to 108.80% of Gross Profit Margin.
- The Interest Expense is -0.18% of Operating Income.
- The Net Earning history of PLL is -54.69% of Total Revenues.
- Per Share Earnings over the last 35 years have been positive in 14 years.
Piedmont Lithium Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Metals & Mining |
| Sector: | Materials |
| Current Symbol: | PLL |
| CUSIP: | 720162 |
| Website: | piedmontlithium.com |
Debt
| Debt-to-Equity Ratio: | 0.08 |
|---|---|
| Current Ratio: | 1.99 |
| Quick Ratio: | 1.93 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
PLL Technical Analysis vs Fundamental Analysis
Sell
38
Piedmont Lithium (PLL)
is a Sell
Is Piedmont Lithium a Buy or a Sell?
-
Piedmont Lithium stock is rated a Sell
The current Piedmont Lithium [PLL] share price is $13.19. The Score for PLL is 38, which is 24% below its historic median score of 50, and infers higher risk than normal.